Compare EDU & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDU | RDY |
|---|---|---|
| Founded | 1993 | 1984 |
| Country | China | India |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 11.6B |
| IPO Year | 2006 | N/A |
| Metric | EDU | RDY |
|---|---|---|
| Price | $58.70 | $14.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $62.80 | $16.90 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 01-28-2026 | 01-20-2026 |
| Dividend Yield | ★ 2.04% | 0.51% |
| EPS Growth | 3.94 | ★ 5.58 |
| EPS | ★ 2.38 | 0.76 |
| Revenue | ★ $5,140,631,000.00 | $3,848,694,754.00 |
| Revenue This Year | $12.44 | $6.12 |
| Revenue Next Year | $10.74 | $2.58 |
| P/E Ratio | $24.63 | ★ $18.50 |
| Revenue Growth | 6.70 | ★ 11.09 |
| 52 Week Low | $40.66 | $12.26 |
| 52 Week High | $64.97 | $16.17 |
| Indicator | EDU | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 48.73 | 58.36 |
| Support Level | $59.35 | $14.00 |
| Resistance Level | $61.97 | $14.23 |
| Average True Range (ATR) | 2.48 | 0.23 |
| MACD | -0.22 | 0.08 |
| Stochastic Oscillator | 36.83 | 86.23 |
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.